cancer-drug-patient-cure.si_A new technique of treating leukemia using a patient’s own immune system which is being called a ‘living drug’ has worked in 88 percent of adults a team of researchers in the US has found. Scientists in New York published a report in Science Magazine in December 2013, hailing the treatment as a breakthrough in the field of cancer immunotherapy, AFP reports. The latest trial, which was published in the journal Science Translational Medicine, involved 16 people with adult B acute Lymphoblastic leukemia (ALL). In the trials 14 of the 16 patients achieved complete remission after their T cells – which play a crucial role in the body’s immune system – were genetically engineered so they could focus on beating back the cancer. The longest remission among the 14 patients is so far about two years according to the lead author of the report, Renier Brentjens, director of cellular therapeutics at Memorial Sloan Kettering Cancer Center in New York. The process involves removing some of a patient’s T-cells and altering them with a gene to make them recognize a protein on the cancer cells called CD19, so that they can attack them but not other cells. Without this genetic alteration T-cells will attack other harmful invaders in the body, but will allow cancer cells to grow. More